利拉鲁肽联合二甲双胍对2型糖尿病患者血糖、血脂、IMT的影响

Effect of liraglutide combined with metformin on blood glucose,blood lipid and IMT of patients with type 2 diabetes mellitus

目的 观察利拉鲁肽联合二甲双胍对2型糖尿病患者血糖、血脂、颈动脉内膜中层厚度(IMT)的影响。方法 85例2型糖尿病患者,以随机数字表法分成对照组(42例)及试验组(43例)。对照组采用二甲双胍治疗,试验组采用利拉鲁肽联合二甲双胍治疗。对比两组治疗前后的血糖指标[糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PBG)、空腹血糖(FPG)]、血脂指标[包括高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、总胆固醇(TC)]及IMT水平,治疗期间的不良反应发生率。结果 治疗后,试验组患者的HbA1c(6.79±0.54)%、2 h PBG(8.72±0.65)mmol/L、FPG(6.74±0.52)mmol/L低于对照组的(8.87±0.65)%、(10.65±0.98)mmol/L、(8.36±0.73)mmol/L,差异具有统计学意义(P<0.05)。治疗后,试验组患者的HDL-C(1.45±0.44)mmol/L高于对照组的(1.25±0.41)mmol/L,LDL-C(2.39±0.44)mmol/L、TG(2.09±0.38)mmol/L、TC(3.19±0.41)mmol/L低于对照组的(3.79±0.51)、(2.61±0.43)、(3.51±0.52)mmol/L,IMT(0.84±0.21)mm小于对照组的(1.14±0.26)mm,差异具有统计学意义(P<0.05)。两组治疗期间的不良反应发生率对比,差异无统计学意义(P>0.05)。结论 2型糖尿病患者应用利拉鲁肽联合二甲双胍治疗具有显著临床效果,可有效降糖、降脂,并改善IMT,且联合用药不会增加不良反应发生率,临床应用价值显著。

Objective To observe the effect of liraglutide combined with metformin on blood sugar,blood lipid and intima-media thickness(IMT)of patients with type 2 diabetes mellitus.Methods A total of 85 patients with type 2 diabetes mellitus were divided into control group(42 cases)and experimental group(43 cases)according to the random numerical table.The control group was treated with metformin,and the experimental group was treated with liraglutide and metformin.Both groups were compared in terms of blood glucose indexes[glycosylated hemoglobin(HbA1c),2 h postprandial blood glucose(2 h PBG),fasting plasma glucose(FPG)],blood lipid indexes[high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),triglycerides(TG),total cholesterol(TC)],IMT level,and incidence of adverse reactions during treatment.Results After treatment,the experimental group had HbA1c of(6.79±0.54)%,2 h PBG of(8.72±0.65)mmol/L,and FPG of(6.74±0.52)mmol/L,which were lower than those of(8.87±0.65)%,(10.65±0.98)mmol/L,and(8.36±0.73)mmol/L in the control group,and the differences were statistically significant(P<0.05).After treatment,HDL-C of(1.45±0.44)mmol/L in the experimental group was higher than that of(1.25±0.41)mmol/L in the control group;the experimental group had LDL-C of(2.39±0.44)mmol/L,TG of(2.09±0.38)mmol/L and TC of(3.19±0.41)mmol/L,which were lower than those of(3.79±0.51),(2.61±0.43)and(3.51±0.52)mmol/L in the control group;IMT of(0.84±0.21)mm in the experimental group was lower than that of(1.14±0.26)mm in the control group;the difference were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Lilalutide combined with metformin for type 2 diabetes mellitus patients has significant clinical effects,which can effectively reduce blood glucose and lipid,and improve IMT,and the combination of drugs will not increase the incidence of adverse reactions,with significant clinical value.